By analyzing existing basic indicators between Anixa Biosciences and DarioHealth, you can compare the effects of market volatilities on both companies' prices and check if they can diversify away market risk if combined in one of your portfolios. You can also utilize pair trading strategies for matching a long position in DarioHealth with a short position in Anixa Biosciences. Check out our
pair correlation module for more information.
Let's begin by analyzing the assets. One of the ways to look at asset utilization of Anixa is to check how much profit was generated for every dollar of assets it reports. Anixa Biosciences shows a negative utilization of assets of -74.88 percent, losing $0.75 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Anixa Biosciences shows how discouraging it operates for each dollar spent on its assets.
Out of tens of thousands of stocks, funds, and ETFs that trade on global exchanges each represent an individual company which you can analyze using comparative analysis. To determine which one of the two entities, such as Anixa or Cue is a better fit for your portfolio, analyzing a few basic fundamental indicators is a good first step.
How important is Anixa Biosciences's Liquidity
Anixa Biosciences
financial leverage refers to using borrowed capital as a funding source to finance Anixa Biosciences ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Anixa Biosciences financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Anixa Biosciences' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Anixa Biosciences' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between Anixa Biosciences's total debt and its cash.
Correlation Between Anixa and Cue Biopharma
In general, Stock analysis is a method for investors and traders to make individual buying and selling decisions. Stock correlation analysis is also essential because it can help investors realize that they may not be as diversified as they think. Risk management strategies are usually required to make sure all portfolios are properly aligned against their risk tolerance level. You can consider holding Anixa Biosciences together with similar or unrelated positions with a negative correlation. For example, you can also add Cue Biopharma to your portfolio. If Cue Biopharma is not perfectly correlated to Anixa Biosciences it will diversify some of the market risks out of the positively correlated stocks in your portfolio. However, the disadvantage of this sort of hedging is that it can potentially affect your investment returns throughout market cycles. When Anixa Biosciences, for example, performs excellent and delivers stable returns, the negatively correlated position you locked in as a hedge may drag your returns down.
Are you currently holding both Anixa Biosciences and Cue Biopharma in your portfolio? Please note if you are using this as a pair-trade strategy between Anixa Biosciences and Cue Biopharma, watch out for correlation discrepancy over time. Relying on the historical price correlations and assuming that it will not change may lead to short-term losses. Please check
pair correlation details between ANIX and CUE for more information.
Breaking down the case for Anixa Biosciences
Cash and Equivalents Breakdown
Let me now analyze Anixa Biosciences cash and equivalents. In accordance with the recently published financial statements, Anixa Biosciences has 9.07
M in Cash and Equivalents. This is 98.9% lower than that of the Healthcare sector and 97.88% lower than that of the
Diagnostics & Research industry. The cash and equivalents for all United States stocks is 99.66% higher than that of the company. As for DarioHealth Corp we see cash and equivalents of 36.91
M, which is 91.38% lower than that of the Diagnostics & Research
| ANIX | 9.07 Million | 1.91 |
| Sector | 428.34 Million | 90.31 |
| DRIO | 36.91 Million | 7.78 |
Anixa Biosciences to slide back in February
The market risk adjusted performance is down to 1.79 as of today. Anixa Biosciences exhibits above-average semi-deviation for your current time horizon. We encourage investors to investigate Anixa Biosciences individually to make sure intended market timing strategies and available technical indicagtors are consistent with their estimates about Anixa Biosciences future systematic risk.
The Bottom Line
While some firms in the diagnostics & research industry are either recovering or due for a correction, Anixa may not be as strong as the others in terms of longer-term growth potentials. With an impartial outlook on the current market volatility, it may be better to hold off any inventment activity and neither pick up nor quit any shares of Anixa Biosciences at this time. The Anixa Biosciences risk-reward trade off is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Anixa Biosciences.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Raphi Shpitalnik is a Junior Member of Macroaxis Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time basis at the beginning of the pandemic and eventually acquired a real taste for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Anixa Biosciences. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
